Astria Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Astria TherapeuticsDer Gewinn des Unternehmens wird voraussichtlich um 6.9% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 88.7% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich um 5.1% pro Jahr wachsen.

Wichtige Informationen

-6.9%

Wachstumsrate der Gewinne

5.1%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	27.6%
Wachstumsrate der Einnahmen	88.7%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	28 Oct 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely

Jul 11

Astria Therapeutics: A Cash-Rich Entrant In An Increasingly Crowded Field

Jun 24

Astria Therapeutics: Too Much Risk, Too Little Reward Despite Near-Term Data Readout

Feb 04

Here's Why We're Not Too Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Situation

Nov 30

We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely

Aug 01

Dr. Chris Morabito is the new medical chief of Astria Therapeutics

Jul 15

Catabasis Pharmaceuticals: Transformation Through Quellis Biosciences Acquisition

Jun 30

Catabasis Pharmaceuticals skyrockets 44% on 7.5% ownership disclosure by RA Capital

Jun 15

Catabasis Pharma shares surge after Quellis Biosciences deal

Jan 29

Will Catabasis Pharmaceuticals (NASDAQ:CATB) Spend Its Cash Wisely?

Dec 10

Catabasis' Catastrophic Failure, And Other News: The Good, Bad And Ugly Of Biopharma

Oct 29

Gewinn- und Umsatzwachstumsprognosen

NasdaqGM:ATXS - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	1	-143	-175	N/A	6
12/31/2025	N/A	-122	-141	N/A	6
12/31/2024	N/A	-97	-84	N/A	6
6/30/2024	N/A	-93	-81	-80	N/A
3/31/2024	N/A	-82	-74	-74	N/A
12/31/2023	N/A	-73	-68	-68	N/A
9/30/2023	N/A	-55	-49	-49	N/A
6/30/2023	N/A	-49	-45	-45	N/A
3/31/2023	N/A	-48	-44	-44	N/A
12/31/2022	N/A	-52	-44	-44	N/A
9/30/2022	N/A	-48	-39	-39	N/A
6/30/2022	N/A	-44	-37	-37	N/A
3/31/2022	N/A	-65	-34	-34	N/A
12/31/2021	N/A	-219	-30	-30	N/A
9/30/2021	N/A	-219	-32	-32	N/A
6/30/2021	N/A	-222	-34	-34	N/A
3/31/2021	N/A	-199	-34	-34	N/A
12/31/2020	N/A	-37	-33	-32	N/A
9/30/2020	N/A	-35	-32	-32	N/A
6/30/2020	N/A	-31	-29	-29	N/A
3/31/2020	N/A	-28	-27	-27	N/A
12/31/2019	N/A	-26	-27	-27	N/A
9/30/2019	N/A	-26	-24	-24	N/A
6/30/2019	N/A	-25	-23	-23	N/A
3/31/2019	N/A	-24	-23	-23	N/A
12/31/2018	N/A	-26	-23	-23	N/A
9/30/2018	0	-25	-24	-24	N/A
6/30/2018	1	-27	-25	-25	N/A
3/31/2018	1	-27	N/A	-26	N/A
12/31/2017	1	-27	N/A	-27	N/A
9/30/2017	0	-31	N/A	-29	N/A
6/30/2017	N/A	-32	N/A	-29	N/A
3/31/2017	N/A	-35	N/A	-32	N/A
12/31/2016	N/A	-36	N/A	-33	N/A
9/30/2016	N/A	-37	N/A	-34	N/A
6/30/2016	N/A	-37	N/A	-35	N/A
3/31/2016	N/A	-36	N/A	-32	N/A
12/31/2015	N/A	-33	N/A	-30	N/A
9/30/2015	N/A	-29	N/A	-27	N/A
6/30/2015	N/A	-27	N/A	-24	N/A
3/31/2015	N/A	-24	N/A	-23	N/A
12/31/2014	N/A	-22	N/A	-20	N/A
9/30/2014	N/A	-21	N/A	-19	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ATXS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: ATXS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: ATXS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: ATXS wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Hohe Wachstumseinnahmen: ATXS wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von ATXS in 3 Jahren voraussichtlich hoch sein wird

Astria Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 23% to US$25.57

Price target decreased by 7.0% to US$20.86

Price target decreased by 8.2% to US$22.43

Price target increased to US$23.67

Price target lowered to US$33.00

Recent updates

European Commission Grants Orphan Medicinal Product Designation for Navenibart, Astria Therapeutics' Investigational Therapy for the Treatment of Hereditary Angioedema

We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely

Astria Therapeutics: A Cash-Rich Entrant In An Increasingly Crowded Field

Astria Therapeutics, Inc. Appoints Sunil Agarwal to Its Board of Directors

Chief Medical Officer notifies of intention to sell stock

Price target increased by 23% to US$25.57

Astria Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Astria Therapeutics: Too Much Risk, Too Little Reward Despite Near-Term Data Readout

Chief Medical Officer notifies of intention to sell stock

Astria Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $125.0106 million.

New major risk - Shareholder dilution

Astria Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $125.0106 million.

New minor risk - Share price stability

We Think Astria Therapeutics (NASDAQ:ATXS) Can Afford To Drive Business Growth

New major risk - Revenue and earnings growth

Price target decreased by 7.0% to US$20.86

Astria Therapeutics, Inc. Presents New Phase 1a Data Confirming Potential for STAR-0125 to Prevent Hereditary Angioedema Attacks with Dosing 2 or 4 Times Per Year at 2023 American College of Allergy, Asthma, and Immunology Annual Scientific Meeting

Astria Therapeutics, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Price target decreased by 8.2% to US$22.43

Astria Therapeutics, Inc. Announces Publication of Star-0215 Preclinical Data in the Journal of Pharmacology and Experimental Therapeutics

We Think Astria Therapeutics (NASDAQ:ATXS) Can Afford To Drive Business Growth

Astria Therapeutics, Inc. Receives Fast Track Designation for Star-0215 for the Treatment of Hereditary Angioedema

Astria Therapeutics, Inc. Appoints John Ruesch as Senior Vice President, Pharmaceutical Sciences and Technical Operations

We're Not Very Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Rate

Astria Therapeutics, Inc. Initiates ALPHA-STAR Phase 1b/2 Clinical Trial of STAR-0215 in People with HAE

Price target increased to US$23.67

Astria Therapeutics, Inc. Announces Positive Preliminary Results from the Phase 1A Clinical Trial of Star-0215 in Healthy Subjects

Here's Why We're Not Too Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Situation

Insufficient new directors

Astria Therapeutics, Inc. Announces Initiation of A Phase 1A Clinical Trial of STAR-0215 in Healthy Subjects

We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely

Astria Therapeutics Announces FDA Clearance of IND Application for STAR-0215, a Monoclonal Antibody Inhibitor of Plasma Kallikrein for Treatment of Hereditary Angioedema

Astria Therapeutics, Inc Appoints Chris Morabito as Chief Medical Officer

Dr. Chris Morabito is the new medical chief of Astria Therapeutics

Astria Therapeutics Presents New Preclinical Data of STAR-0215, in Development for Treatment of Hereditary Angioedema

Astria Therapeutics, Inc.(NasdaqGM:ATXS) dropped from Russell Microcap Value Index

Insufficient new directors

Insufficient new directors

Catabasis Pharmaceuticals: Transformation Through Quellis Biosciences Acquisition

Catabasis Pharmaceuticals, Inc.(NasdaqGM:CATB) dropped from Russell 3000E Value Index

Catabasis Pharmaceuticals skyrockets 44% on 7.5% ownership disclosure by RA Capital

Catabasis Pharmaceuticals Provides A Corporate Update

Chief Medical Officer & Senior VP of Clinical Development has left the company

Independent Director has left the company

Catabasis Pharmaceuticals, Inc. Announces Executive Appointments

Catabasis Pharma shares surge after Quellis Biosciences deal

New 90-day high: US$2.75

Will Catabasis Pharmaceuticals (NASDAQ:CATB) Spend Its Cash Wisely?

New 90-day low: US$1.32

Catabasis' Catastrophic Failure, And Other News: The Good, Bad And Ugly Of Biopharma

Catabasis Pharmaceuticals Announces Top-Line Results for the Phase 3 PolarisDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy

New 90-day low: US$5.41

Price target lowered to US$33.00

Catabasis Pharmaceuticals, Inc. Appoints Noah Clauser as Chief Financial Officer

New 90-day high - US$7.55

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken